Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Zanni

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
JACC. Advances|August 21, 2025
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIVKristine M Erlandson, Ariela R Orkaby, Triin Umbleja, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2022
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United StatesMarkella V Zanni, Borek Foldyna, Sara McCallum, et al.
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
HIV Research & Clinical Practice|March 13, 2020
Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordinationKathleen V Fitch, Emma M Kileel, Sara E Looby, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2025
Factors Affecting Risk of CVD Events in a Global CVD Prevention Cohort of People with HIVSteven K Grinspoon, Maya Watanabe, Heather J Ribaudo, et al.
JACC. Cardiovascular Imaging|December 1, 2025
Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE TrialBorek Foldyna, Ibrahim Hadzic, Thomas Mayrhofer, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
JACC. Advances|August 21, 2025
Frailty, Pitavastatin, and Major Adverse Cardiovascular Events Among People With HIVKristine M Erlandson, Ariela R Orkaby, Triin Umbleja, et al.
The Journal of Infectious Diseases|July 10, 2020
Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE TrialCarl J Fichtenbaum, Heather J Ribaudo, Jorge Leon-Cruz, et al.
American Heart Journal|April 1, 2019
Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkersUdo Hoffmann, Michael T Lu, Devvora Olalere, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2022
Sex Differences in Subclinical Atherosclerosis and Systemic Immune Activation/Inflammation Among People With Human Immunodeficiency Virus in the United StatesMarkella V Zanni, Borek Foldyna, Sara McCallum, et al.
AIDS (London, England)|November 11, 2025
Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE TrialMarissa R Diggs, Sarah M Chu, Kathleen V Fitch, et al.
HIV Research & Clinical Practice|March 13, 2020
Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordinationKathleen V Fitch, Emma M Kileel, Sara E Looby, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 2, 2022
Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral TherapySara E Looby, Amy Kantor, Tricia H Burdo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 26, 2025
Factors Affecting Risk of CVD Events in a Global CVD Prevention Cohort of People with HIVSteven K Grinspoon, Maya Watanabe, Heather J Ribaudo, et al.
JACC. Cardiovascular Imaging|December 1, 2025
Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE TrialBorek Foldyna, Ibrahim Hadzic, Thomas Mayrhofer, et al.
JACC. Advances|June 28, 2024
Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk PopulationsJulia Karady, Michael T Lu, Göran Bergström, et al.
Pageof 14